Despite the impending trade tariffs imposed by the Trump administration, prominent Indian manufacturers in the pharmaceutical and steel sectors have downplayed concerns about the negative impact on exports to the US.

BulletsIn

• Indian pharma and steel sectors remain largely unaffected by impending US trade tariffs.
• Two prominent manufacturers in these sectors have expressed confidence in exports continuing without major disruptions.
• Indian pharma exports to the US are expected to remain stable despite the tariffs.
• Indian steel manufacturers also feel insulated from the potential impact of tariffs.
• Indian companies in these sectors have diversified markets, reducing dependence on the US.
• The US remains a major destination for Indian pharmaceutical exports, particularly generic drugs.
• Indian steel companies are investing in innovation and alternative markets to mitigate tariff impact.
• Both sectors are optimistic about maintaining strong business relations with the US.
• Experts suggest that Indian companies’ operational agility helps them adjust to external trade challenges.
• Indian manufacturers are also exploring opportunities in other global markets to offset potential losses from the US market.